Amivantamab Plus Chemotherapy With or Without Lazertinib for EGFR-Mutant Advanced NSCLC After Disease Progression on Osimertinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase 3 MARIPOSA-2 study
Ann. Oncol 2023 Oct 23;[EPub Ahead of Print], A Passaro, J Wang, Y Wang, SH Lee, B Melosky, JY Shih, J Wang, K Azuma, O Juan-Vidal, M Cobo, E Felip, N Girard, AB Cortot, R Califano, F Cappuzzo, S Owen, S Popat, JL Tan, J Salinas, P Tomasini, RD Gentzler, WN William, KL Reckamp, T Takahashi, S Ganguly, DM Kowalski, A Bearz, M MacKean, P Barala, AB Bourla, A Girvin, J Greger, D Millington, M Withelder, J Xie, T Sun, S Shah, B Diorio, RE Knoblauch, JM Bauml, RG Campelo, BC ChoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.